Head and Neck Cancer News
In an international, multicenter collaboration, experts modified the RECIST criteria for use as objective endpoints in clinical trials of retinoblastoma therapies.
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
A team of investigators conducted a randomized controlled trial to assess outcomes following salvage endoscopic surgery vs radiation therapy in patients with resectable, locally recurrent nasopharyngeal cancer.
Investigators of the phase 3 KESTREL trial recruited 823 patients with previously untreated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Investigators tested the efficacy of reduced-dose radiation plus cisplatin in patients with good-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC).
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Population-based study demonstrated an association between patient-reported outcomes and ED visits/unplanned hospitalizations among patients with head and neck cancer.
Researchers sought to determine the effect of PDC on venous thromboembolism and bleeding events in patients with HNC undergoing surgery.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
This analysis identified the factors for poor long-term survival in radiotherapy (RT)-treated patients with oropharyngeal cancer (OPC).
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Experts have developed a new tool for surgical prioritization and ranking for patients with head and neck cancer in a scarce-resource settings associated with the COVID-19 pandemic.
Outcomes and survival improved for early-stage oropharyngeal cancer, but not other cancers.
Single-center study reports on the effects of oropharyngeal cancer treatment at 3, 6, and 12 months after chemoradiotherapy or radiotherapy alone, and with and without a feeding tube.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
The approval is based on evidence that the vaccine can prevent anogenital infections, with an ongoing trial looking at throat infection prevention in men likely to be critical for continued approval.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.